1 week Ago By ABMN Staff
Vanguard Group Inc. increased its holdings in shares of Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ) by 14.
6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,818,898 shares of the company’s stock after buying an additional 615,211 shares during the period. Vanguard Group Inc.
owned about 0.06% of Kura Oncology worth $41,973,000 at the end of the most recent quarter. A number of other hedge funds also recently added to or reduced their stakes in the business.
Geode Capital Management LLC grew its stake in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares in the last quarter.
Franklin Resources Inc. boosted its holdings in Kura Oncology by 1.5% in the third quarter.
Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after purchasing an additional 23,113 shares during the period. Charles Schwab Investment Management Inc.
grew its stake in Kura Oncology by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 635,494 shares of the company’s stock worth $5,535,000 after purchasing an additional 10,542 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Kura Oncology by 0.
8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after purchasing an additional 3,092 shares during the period.
Finally, Barclays PLC raised its position in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after purchasing an additional 84,563 shares in the last quarter.
Insider Transactions at Kura Oncology In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.
63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91.
This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website .
Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.
81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11.
The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Over the last ninety days, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.
Kura Oncology Price Performance Kura Oncology ( NASDAQ:KURA – Get Free Report ) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.
65) by $0.43. The firm had revenue of $53.
88 million during the quarter, compared to analysts’ expectations of $57.96 million. As a group, sell-side analysts anticipate that Kura Oncology, Inc.
will post -2.44 EPS for the current year. Wall Street Analysts Forecast Growth KURA has been the subject of a number of analyst reports.
Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th.
JMP Securities reissued a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank decreased their price objective on shares of Kura Oncology from $18.
00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th.
Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.50.
View Our Latest Report on Kura Oncology Kura Oncology Company Profile ( Free Report ) Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Further Reading Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
